The Niche

More shots with mesenchymal stem cells

Yesterday, I reported on the failure of two late stage trials exploring mesenchymal stem cells to quell the potentally fatal immune response in graft versus host disease. Those trials were led by Osiris, a company in Maryland, which still hopes to look through its data and ongoing trials for signs of efficacy. See Stem-cell drug fails crucial trials 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE